IMA Advisory Services’s Teva Pharmaceuticals TEVA Stock Holding History

IMA Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63K	Buy	48 +24	+100%	+$799	﹤0.01%	1147
2026 Q1	$722	Hold	24	–	–	﹤0.01%	827
2025 Q4	$749	Buy	+24	New	+$591	﹤0.01%	820

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

IMA Advisory Services's TEVA Position: Q2 2026 in Review

IMA Advisory Services increased its Teva Pharmaceuticals (TEVA) stake by 100% in Q2 2026, buying an estimated $799 and bringing the position to 48 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

IMA Advisory Services first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

IMA Advisory Services held 48 shares of Teva Pharmaceuticals worth $1.63K as of Q2 2026.
IMA Advisory Services bought 24 Teva Pharmaceuticals shares in Q2 2026, an estimated $799.
Teva Pharmaceuticals made up ﹤0.01% of IMA Advisory Services's portfolio in Q2 2026, its #1147 holding.
IMA Advisory Services first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on IMA Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.